In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Vertex acquires Aurora for $570mm

Executive Summary

In a tax-free stock swap worth $570mm, Vertex Pharmaceuticals will acquire fluorescence assay and screening platform company Aurora Biosciences. Based on the companies’ trading prices before announcement, Vertex will pay a (pr)56% premium for the shares, at $24.34 apiece. Each Aurora share converts to 0.62 shares of Vertex common; Vertex will issue about 14mm new shares.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
      • Genomics-Proteomics
      • Molecular Diversity
    • Pharmacogenetics-Pharmacogenomics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Stock
    • Full Acquisition
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register